Alembic Pharma Ltd
Microcap 250
₹810.95
-0.67%
Delayed · cached 15 min
Fair value analysis
APLLTD
Alembic Pharma Ltd
₹816.40
Close used for this calculation
₹838.92Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
59/100
Quality radar
Consensus fair value
₹838.92
Near FV▲ +2.8% against the close used
Model range ₹294.82 – ₹1,546.08
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹294.82Fair value₹838.92Bull₹1,546.08
FairClose
52-week traded range
52W low ₹646.5552W high ₹978.10
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
Alembic Pharma Ltd closed at ₹816.40, 2.7% below the consensus fair value of ₹838.92 drawn from 10 valuation models.
Financial DNA score 59/100 — Good. P/E of 21.4x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹294.82
-63.9%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹498.27
-39.0%
√(22.5 × EPS × BVPS)
EPS=34.33, BVPS=321.42 · outside Graham range (P/E 21.4, P/B 2.5) — asset-light, treat as a rough floor
Graham Formula
₹1,546.08
+89.4%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹1,225.58
+50.1%
EPS × 35.7x (sector P/E)
EPS=34.33, Sector P/E=35.7x
Peter Lynch (PEG)
₹858.25
+5.1%
EPS × Growth% (PEG = 1 is fair)
EPS=34.33, g=25%
EV/EBITDA
₹1,254.31
+53.6%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=14.4B
Dividend Discount (DDM)
₹652.47
-20.1%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=12.08, r=10%, g=8%
Book Value (P/B)
₹594.62
-27.2%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=321.42, ROE=13.4%, g=6%, r=10%
Reverse DCF
₹816.40
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 9.5% | Historical: 25%
Margin of Safety
₹668.39
-18.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=891.19, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.